How Many Batches Need Nitrosamine Confirmatory Testing? Sampling Strategy Explained

How Many Batches Need Nitrosamine Confirmatory Testing? Sampling Strategy Explained

Introduction:

Sponsors and manufacturers often ask us the same question once a risk assessment flags a possible nitrosamine concern: how many lots do we actually have to test? Understanding Nitrosamine Confirmatory Testing Batch Requirements is critical because testing too few batches can leave a real contamination pattern undetected, while testing too many wastes time, material, and budget.

Nitrosamine impurities, including N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA), and nitrosamine drug substance-related impurities (NDSRIs), have become a major focus of pharmaceutical quality oversight because several compounds in this group are associated with potential carcinogenic risk.

The answer to the batch question is not one number applied everywhere. Regulatory guidance describes a three-step approach: risk assessment, confirmatory testing where a risk is identified, and reporting of changes. The number of batches you test sits inside step two and must be justified by your own risk assessment, the market you supply, and the regulatory context. This article explains how to make that decision defensibly, drawing on how an experienced analytical laboratory approaches nitrosamine analysis. Regulatory expectations evolve, so always confirm requirements against the current FDA, EMA, and Health Canada documents for your product.

Summary:

  • There is no universal rule that every product needs exactly three batches, or any other fixed number. FDA expects a risk-based, representative selection of batches.
  • EMA and Health Canada give specific benchmarks for marketed products: 10% of annual batches or three batches per year, whichever is higher, when the nitrosamine source is understood and levels are consistent. If fewer than three batches are made annually, test all of them.
  • For new applications with an identified risk, Health Canada recommends at least six pilot-scale or three commercial-scale batches, and more for high-risk products.
  • The batch count is driven by the risk assessment: API manufacturing route, formulation and excipients, manufacturing sites, raw material sources, and historical data.
  • Representative selection matters more than the number alone: cover different manufacturing periods, API and excipient lots, sites, and worst-case conditions.
  • Use validated, sufficiently sensitive methods such as LC-MS/MS, GC-MS/MS, or HRMS, with a limit of quantitation suited to the acceptable intake (AI) limit.
  • Include stability samples where nitrosamine levels could rise during shelf life.
  • Expand testing after supplier or process changes, results near the AI limit, or newly identified risks, and document the rationale.

1: How Many Batches Need Nitrosamine Confirmatory Testing?

Short answer: There is no single batch count for every product, but regulators give useful benchmarks. For marketed products where the nitrosamine source is understood and levels are consistent, EMA and Health Canada recommend testing 10% of annual batches or three batches per year, whichever is higher. FDA expects a risk-based, representative selection without a fixed number.

That is why “three batches” works as a planning figure in some contexts but should never be treated as a universal rule. The right number follows your risk assessment and the market you supply, and you must be able to defend it.

A practical way to frame it:

  • Low residual risk, stable process, results far below the AI limit: a smaller, representative set (often three batches) may be defensible.
  • Moderate risk or limited process history: test additional batches and include worst-case conditions.
  • High risk, or results approaching the AI limit: expand testing, investigate root cause, and consider ongoing monitoring.

2: FDA, EMA, and Health Canada: What Do Regulators Recommend for Batch Numbers?

Expectations differ by agency and by context, so batch numbers should never be copied from one market to another without checking the current guidance.

FDA Recommendations

FDA’s September 2024 guidance, Control of Nitrosamine Impurities in Human Drugs, recommends that manufacturers conduct risk assessments, perform appropriate confirmatory testing, and establish controls to prevent or reduce unacceptable nitrosamine impurities. FDA does not prescribe one fixed number of batches. Manufacturers should select representative batches based on product-specific risks. The agency emphasizes evaluating:

  • Batch-to-batch variability
  • Different suppliers and vendors
  • Sample numbers and quantities from each relevant lot
  • Potential nitrosamine sources throughout the supply chain

So testing three batches may be appropriate in one situation and insufficient in another.

EMA Recommendations

For marketed products where the nitrosamine source is identified and well understood, and impurity levels are expected to stay consistent between batches, EMA recommends testing 10% of annual batches or three batches per year, whichever is higher. If fewer than three batches are made annually, all batches should be tested. The program should include newly manufactured batches and retained samples of batches still within expiry. Additional batches may be needed when several manufacturing sites, processes, or sources of at-risk raw materials are involved.

Health Canada Recommendations

Health Canada also follows a risk-based approach. For marketed products it recommends:

  • Representative batch testing based on identified risks
  • Testing 10% of annual batches or three batches per year, whichever is higher, when the root cause is understood and batch-to-batch levels are expected to be consistent
  • Testing all batches within expiry when fewer than three are manufactured annually
  • Additional testing when nitrosamine levels approach or exceed acceptable intake limits

For new drug submissions and relevant applications with an identified nitrosamine risk, Health Canada recommends at least six pilot-scale or three commercial-scale batches, with higher numbers for high-risk products. Stability testing should also be considered when levels could increase during storage.

Regulatory Comparison of Batch Requirements

Regulatory SourceRecommended Batch-Testing Approach
US FDARisk-based selection of representative batches; no universal fixed batch count
EMA, marketed products10% of annual batches or 3 per year, whichever is higher, when the source is understood and levels are consistent
Health Canada, marketed products10% of annual batches or 3 per year, whichever is higher, under defined conditions
Health Canada, relevant new applicationsAt least 6 pilot-scale or 3 commercial-scale batches when a risk is identified

These recommendations apply in specific regulatory contexts and are not interchangeable. Consult the current guidance for your target market and submission type.


3: What Does Confirmatory Testing Mean in the Nitrosamine Framework?

Confirmatory testing is the quantitative analysis of drug substance or drug product batches, using a validated and sufficiently sensitive method, to confirm whether a nitrosamine impurity is actually present and at what level.

It follows a risk assessment that has identified a plausible pathway for formation or contamination. A risk assessment is a desk-based evaluation. Confirmatory testing is the laboratory evidence that either confirms or rules out the concern. If a nitrosamine is detected above the reporting threshold, further actions such as root-cause investigation, control strategy changes, and regulatory notification may follow.


4: Factors That Determine Nitrosamine Confirmatory Testing Batch Requirements

The number of batches to test depends on how much uncertainty remains after the risk assessment. The more variability or unknowns, the more batches you need to build confidence.

FactorWhy It Affects Batch NumberDirection of Impact
Root cause of riskContamination from a specific raw material or solvent lot varies more than a stable process-inherent pathwayMore batches if source-dependent
Process variabilityVariable reaction conditions, temperatures, or hold times change formation levelsMore batches if variable
Number of suppliers or sourcesEach API, excipient, or solvent source may carry different impurity profilesTest across sources
Number of manufacturing sitesEquipment, utilities, and recovered solvents differ between sitesTest per site
Packaging and storageNitrite in packaging or stability-driven formation can change levels over timeInclude stability or aged samples
Margin to the AI limitResults close to the limit need tighter statistical confidenceMore batches as margin shrinks
Product historyNew products have little data; established products have trend dataMore batches for new products
Dosage strengths and formulationsDifferent excipient ratios may alter formationBracket the strengths

API Manufacturing Process

The API manufacturing route is one of the most important drivers of batch selection. Nitrosamines may form when secondary or tertiary amines meet nitrosating agents under suitable conditions. Potential sources include:

  • Nitrite-containing raw materials and reagents
  • Secondary and tertiary amine-containing intermediates
  • Recovered solvents and recycled process materials
  • Cross-contamination from shared equipment
  • Changes in reaction conditions, including pH and temperature
  • Contaminated process water or raw materials

If different API routes carry different risks, evaluate whether batches from each route need confirmatory testing. Our nitrosamine risk assessment services for API suppliers show how these route-level pathways are mapped before a batch plan is set.

Formulation Composition

Drug product formulations can add formation risk even when the API is clean. Nitrite impurities in excipients may react with amine-containing APIs or other components during manufacturing or storage. Consider:

  • Excipient supplier variability and nitrite levels
  • API-excipient compatibility
  • Moisture content and formulation pH
  • Manufacturing temperature and processing conditions
  • Packaging materials and storage conditions

For a deeper look at how these variables interact, see our guide to nitrosamine formation risk in drug products.

Manufacturing Site and Process Variability

Products made at several facilities can behave differently. Equipment, process conditions, raw materials, and environmental controls vary between sites and production lines. Assess whether batches from each site or line adequately represent the identified risks rather than assuming one facility speaks for all.

Historical Analytical Data

Existing data can justify a smaller plan or reveal the need for a larger one. Review:

  • Previous nitrosamine screening results
  • Historical batch testing data
  • Deviations and out-of-specification investigations
  • Supplier qualification records and process validation results
  • Changes in materials or procedures

Historical data must be scientifically relevant, reliable, and representative of the current process. Where an NDSRI is possible, nitrosamine risk assessment and trace-level NDSRI testing helps establish whether past results are sensitive enough to rely on.


5: Building a Defensible Nitrosamine Sampling Strategy

A defensible sampling strategy defines which batches, which units, and which time points you test, and explains why each choice represents the real-world worst case.

Sampling Across Batches

Choose batches that capture the true range of your manufacturing reality, not just the most convenient lots. Useful selection principles include:

  • Include batches made with different lots of the highest-risk raw material
  • Include batches from each manufacturing site and each equipment train
  • Include the oldest and newest commercial batches where practical
  • Include batches made at the edges of validated process ranges
  • Include batches packaged in each primary container system
  • Retain a rationale for any batch you exclude

Include worst-case manufacturing conditions, supported by scientific evidence rather than assumption. Examples include:

  • Higher processing temperatures
  • Longer manufacturing or holding times
  • Increased moisture exposure
  • Higher concentrations of nitrite-containing materials
  • Formulation conditions that favor nitrosation
  • Extended storage periods

Sampling Within a Batch

Each batch must be sampled so that the result represents the whole lot. A single tablet or vial is rarely enough. Typical good practice includes:

  • Taking samples from multiple points across the batch (beginning, middle, and end of a run)
  • Preparing a composite from an appropriate number of dosage units as defined in the validated method
  • Using appropriate, pre-cleaned, nitrosamine-free containers and consumables to avoid artifact contamination
  • Controlling sample preparation conditions, since some matrices can generate nitrosamines artificially during extraction if nitrite and amines are both present
  • Recording sample identity, chain of custody, and storage conditions

Sampling Across Time

Where the formation pathway can continue after release, include stability or aged samples. This is especially relevant when nitrosamine formation is linked to nitrite in excipients or to the packaging system. Testing at release alone may understate the level seen late in shelf life.


6: How Does Stability Testing Influence Nitrosamine Batch Selection?

Stability testing matters because nitrosamine impurities can form or increase during shelf life. A batch that meets acceptance criteria at release may not show the same profile after prolonged storage. Evaluate possible formation under:

  • Long-term storage conditions
  • Accelerated stability conditions
  • Different packaging configurations
  • High-moisture conditions, where relevant
  • Temperature variations that could drive chemical reactions

For example, if an API contains an amine functional group and the formulation contains nitrite impurities, investigate whether nitrosamines can form on storage. Stability studies should include suitable time points and methods able to detect changes in concentration. Health Canada specifically recommends stability testing when levels could increase over time or when that possibility is unclear.


7: Step-by-Step Workflow for a Nitrosamine Confirmatory Testing Plan

A defensible plan combines risk assessment, representative batch selection, sound sample handling, and validated testing. A practical workflow:

  1. Perform a comprehensive risk assessment. Identify potential sources in the API, drug product, excipients, raw materials, process, and packaging, covering both direct contamination and in-process formation.
  2. Define the batch population. Count annual batches and classify them by site, API supplier, excipient supplier, process, strength, and production period.
  3. Identify high-risk batches. Prioritize batches linked to formation pathways, such as higher-nitrite excipients or processes involving secondary amines and nitrosating agents.
  4. Set the testing frequency. Combine the applicable regulatory recommendation with the product-specific risk assessment, and document the justification in the quality system.
  5. Run confirmatory analysis. Use a validated, sufficiently sensitive method with suitable specificity, accuracy, precision, linearity, and sensitivity.
  6. Evaluate results and set controls. Compare results with the AI limit, review batch-to-batch trends, and investigate any unacceptable or unexpected level, including whether more batches need testing.

Batch Requirements by Product Scenario

The right batch strategy differs for drug substances and drug products, and for single-site versus multi-site supply.

ScenarioTypical Approach (Risk-Based)Key Consideration
Drug substance, single site, stable processRepresentative set of commercial batches (often three)Cover multiple solvent and reagent lots
Drug substance, recovered solvents or reagentsExpanded set including worst-case recovery cyclesCarryover varies lot to lot
Drug product, single strengthRepresentative commercial batchesInclude different API lots
Drug product, multiple strengthsBracketing across strengths and formulationsExcipient ratios may change nitrite load
Multiple manufacturing sitesTest batches from each siteSite-specific equipment and utilities
New product with limited historyAdditional batches, plus stability samplesLittle trend data available
Nitrosamine drug substance-related impurity (NDSRI) riskExpanded testing and stability evaluationFormation can occur during storage

These are illustrative frameworks based on common industry practice and the regulatory benchmarks above, not mandates. Your own risk assessment should decide the final plan.

Peptide therapeutics and biologics deserve special attention. Peptide APIs often contain amine functionality and are made through multi-step synthesis, so batch plans should reflect that chemistry. See our resources on nitrosamine testing for peptide and GLP-1 products and nitrosamine risk assessment for peptide APIs. For biological products, the nitrosamine compliance strategy for biosimilars explains how risk-based thinking applies to biosimilar programs.


Which Analytical Method Supports Confirmatory Testing?

The method must be validated and sensitive enough to quantify nitrosamines at or below the acceptable intake limit. Most laboratories use LC-MS/MS or GC-MS/MS, with high-resolution mass spectrometry used for confirmation or for complex matrices. Method validation should address specificity, accuracy, precision, linearity, range, and limit of quantitation, aligned with ICH Q2(R2) principles.

LC-MS/MS

LC-MS/MS is widely used for nitrosamines in APIs and finished drug products because of its sensitivity and selectivity. Key advantages:

  • High sensitivity for trace-level detection
  • Selective identification through multiple reaction monitoring (MRM)
  • Suitability for complex pharmaceutical matrices
  • Quantitation against appropriate reference standards
  • Applicability to several small-molecule nitrosamines and NDSRIs, depending on method design

GC-MS and GC-MS/MS

GC-MS suits volatile, thermally stable nitrosamines. It supports analysis of volatile nitrosamines, residual impurities, and contamination from solvents and process materials. GC-MS/MS adds selectivity and sensitivity, which helps when complex matrices interfere with conventional measurements.

High-Resolution Mass Spectrometry (HRMS)

HRMS supports investigations by providing accurate-mass and structural information. It is useful for unexpected nitrosamine-related signals, potential NDSRIs, impurity characterization, and unknown degradation or reaction products.

Comparison of Analytical Techniques

TechniquePrimary ApplicationKey Advantage
LC-MS/MSSmall-molecule nitrosamines and suitable NDSRIsSensitive quantitative analysis
GC-MSVolatile nitrosaminesSuited to volatile compounds
GC-MS/MSTrace-level volatile nitrosaminesImproved selectivity
LC-HRMSUnknown impurity investigationAccurate mass and structural information

Choose the technique according to the physicochemical properties of the target nitrosamine, the sample matrix, and the required detection limits. The limit of quantitation (LOQ) should suit the relevant AI limit, considering maximum daily dose and the sample preparation procedure.

Two practical points often decide whether a batch plan succeeds:

  • Sensitivity margin: the limit of quantitation should sit comfortably below the AI limit so that a “not detected” result is meaningful
  • Matrix effects and artifact formation: poorly designed sample preparation can create false positives or mask true positives

A qualified laboratory with deep mass spectrometry experience helps avoid spending batches on data that cannot be defended. Learn more about our nitrosamine analysis capabilities.


8: When Should Additional Batches Undergo Nitrosamine Testing?

Additional testing is needed when new information suggests existing results no longer represent the product’s nitrosamine risk. Consider expanding the program when:

  1. Levels approach the AI limit. If testing finds levels near or above the limit, evaluate more batches to understand the extent.
  2. Raw material suppliers change. A new API, excipient, solvent, or reagent supplier may bring new precursors or contamination risks.
  3. Manufacturing processes change. Modified temperature, pH, reaction time, solvent recovery, or material handling can affect formation.
  4. New facilities come online. Technology transfers and site changes need their own assessment.
  5. Stability results are unexpected. If levels rise during storage, investigate additional stability samples and batches.
  6. New nitrosamine impurities are identified. Newly recognized risks may call for new methods, batch testing, and an updated risk assessment.

What Happens After the Results Come Back?

Results determine whether testing stops, expands, or triggers corrective action.

  • Not detected or well below the AI limit across all batches: document the outcome and justify any reduction in routine monitoring
  • Detected below the AI limit: consider additional batches, trending, and periodic retesting to confirm stability of the result
  • Detected at or above the AI limit: initiate root-cause investigation, assess patient risk, implement control measures, and follow regulatory reporting expectations for your jurisdiction

If a specific lot of a raw material or solvent drove a high result, expand testing to other batches made with related lots rather than assuming the finding is isolated.

Documentation Regulators and Inspectors Expect

A complete package links the risk assessment to the batch plan, the method, and the conclusion. Maintain:

  • Nitrosamine risk assessment reports and the specific risks identified
  • Batch selection justification
  • Manufacturing site and supplier information
  • Sampling plans and protocols, including chain of custody
  • Analytical method validation reports
  • Reference standard qualification records
  • Batch-wise analytical results
  • Stability testing data
  • Deviations and investigation reports
  • Corrective and preventive action (CAPA) documentation
  • Ongoing monitoring and periodic risk assessment records
  • The decision on ongoing monitoring

Common Mistakes in Choosing Batches

Common MistakePotential ConsequenceRecommended Approach
Testing only one convenient batchManufacturing variability is overlookedSelect representative batches based on risk
Ignoring supplier differencesRaw material-related risks stay unidentifiedInclude relevant supplier and material variations
Applying three batches as a universal ruleRegulatory expectations may not be metFollow market-specific guidance
Ignoring retained batchesHistorical market exposure goes unassessedInclude relevant batches within expiry
Using an insufficiently sensitive methodLow-level impurities remain undetectedSet an appropriate LOQ below the AI limit
Ignoring stability-related formationImpurities may rise during shelf lifeEvaluate relevant stability samples
Failing to document batch selectionScientific justification is hard to demonstrateMaintain a written sampling rationale

A robust strategy rests on analytical data, manufacturing knowledge, and a documented risk assessment rather than a predetermined batch count. Review the sampling strategy whenever supplier changes, new manufacturing information, or regulatory updates affect the original risk assessment.

How ResolveMass Laboratories Supports Nitrosamine Confirmatory Testing

ResolveMass supports pharmaceutical and biotechnology companies with analytical testing and characterization relevant to nitrosamine investigations and impurity control. Selecting methods, setting suitable detection limits, and interpreting batch-wise results are central to that work. Relevant capabilities include:

  • LC-MS/MS analysis: sensitive quantitative analysis of targeted nitrosamine impurities
  • GC-MS and GC-MS/MS: analysis of volatile nitrosamines and related impurities
  • High-resolution mass spectrometry (HRMS): investigation and characterization of unknown impurities
  • Method development and validation: fit-for-purpose procedures for pharmaceutical samples
  • Impurity profiling: investigation of impurities arising from manufacturing processes, raw materials, and degradation pathways
  • Analytical data support: scientifically documented results to support quality investigations and regulatory activities

Combining the right techniques with a scientifically justified testing approach helps manufacturers strengthen nitrosamine control strategies and make better-informed quality decisions.


Conclusion:

There is no single answer to how many batches need confirmatory testing, but the principle is clear: the batch count must be justified by risk and supported by representative sampling. Understanding Nitrosamine Confirmatory Testing Batch Requirements means weighing regulatory benchmarks, process variability, material sources, manufacturing sites, packaging, stability behavior, and the margin to the acceptable intake limit, then documenting that reasoning clearly.

EMA and Health Canada recommend 10% of annual batches or three per year, whichever is higher, for marketed products under defined conditions, and Health Canada adds at least six pilot-scale or three commercial-scale batches for relevant new applications. These recommendations are not interchangeable, so the most effective approach is a risk-based sampling strategy backed by validated methods, representative batch selection, stability assessment, and documented scientific justification.


Frequently Asked Questions:

1. What is the EMA recommendation for nitrosamine batch testing?

For applicable marketed products where the nitrosamine source is understood and batch-to-batch levels are expected to remain consistent, EMA recommends testing 10% of annual batches or three batches per year, whichever is higher.

2. How many batches should be tested for a new drug application?

The number depends on the regulatory authority and application type. Health Canada recommends at least six pilot-scale batches or three commercial-scale batches for relevant new applications where a nitrosamine risk is identified.

3. Should nitrosamine confirmatory testing be performed on API or finished drug products?

Testing may be required for both, depending on the identified risk. Finished drug product testing is important because nitrosamines may form during formulation, manufacturing, or storage.

4. What is the difference between nitrosamine screening and confirmatory testing?

Screening identifies potential nitrosamine impurities and evaluates their possible presence. Confirmatory testing establishes the identity and concentration of targeted impurities using appropriately validated analytical methods.

Need Support With Peptide CDMO Scale-Up?

Partner with ResolveMass Laboratories Inc. for specialized peptide characterization, analytical testing, impurity profiling, and CMC development support.

Reference

About the Author

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top
Review Your Cart
0
Add Coupon Code
Subtotal